Amphastar Pharmaceuticals delivered results in Q2 that surpassed Wall Street expectations, reflecting continued strength across its diversified product portfolio and new product introductions. Management pointed to robust demand for commercial brands like BAQSIMI and Primatene MIST, as well as the successful launch of ipratropium bromide, as key drivers behind the quarter’s growth. CEO Bill Peters emphasized the company's progress in expanding manufacturing capabilities and advancing its develop

AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.

New product launches drove 5% revenue growth and margin expansion.

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 5.4% year on year to $183.9 million. Its non-GAAP profit of $0.91 per share was 48.3% above analysts’ consensus estimates.

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amphastar (AMPH) delivered earnings and revenue surprises of +37.88% and +1.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported second-quarter 2026 revenue growth, supported by recently launched products including ipratropium bromide inhalation, while management said it is addressing an FDA warning letter at its IMS subsidiary and continuing investments in its pipeline and U.S

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 5.4% year on year to $183.9 million. Its non-GAAP profit of $0.91 per share was 48.3% above analysts’ consensus estimates.

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amphastar Pharmaceuticals has gotten torched over the last six months - since January 2026, its stock price has dropped 27.6% to $18.92 per share. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.